Latest Research
All publications from the Cancer3.AI database, newest first.
Bladder Outlet Obstruction Secondary to a Prostatic Cyst in a Young Adult: A Rare Case Report.
K C S, et al
A rare case of bladder outlet obstruction caused by a prostatic midline cyst in a young adult without an enlarged prostate has been described in the journal Clinical Case Reports. The obstruction was attributed to incomplete regression of the Müllerian duct, an embryological remnant that can form cysts in or around the prostate gland. The patient presented with urinary retention and was successfully diagnosed through ultrasonography and cystoscopy, then treated with urethral catheterization and surgical cyst deroofing, a minimally invasive procedure that removes the roof of the cyst to allow drainage. This case highlights that prostatic cysts should be considered as a potential cause of bladder outlet obstruction even in young men without prostate enlargement, a diagnosis that is often overlooked. Clinicians are encouraged to include transrectal ultrasound and MRI in the diagnostic workup when conventional explanations for urinary obstruction are absent.
Clinical case reports
Source →Myeloid/lymphoid precursor cell neoplasms and mixed phenotype acute leukemias: A Bone Marrow Workshop Report from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting, Dubrovnik, 2024.
Saft L, et al
Researchers from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting in Dubrovnik, 2024, examined 55 complex bone marrow cases involving rare and difficult-to-classify blood cancers, including mixed-phenotype acute leukemias (MPALs) and related disorders. A key finding was that a large proportion of cases initially labeled as ambiguous or mixed-lineage leukemias were reclassified under newer WHO and International Consensus Classification criteria as acute myeloid leukemia with myelodysplasia-related changes (AML-MR) or AML with TP53 mutations. Notably, TP53 mutations were absent in immunophenotypically defined MPAL cases, suggesting that the presence of this mutation may help distinguish true MPAL from AML-MR masquerading as mixed phenotype. The study also highlighted significant diagnostic overlap between certain T-cell and B-cell precursor leukemias and genetically defined MPAL subtypes, posing challenges for accurate classification. The authors propose a genomic classification framework to better separate AML-MR from precursor lymphoid neoplasms and true MPAL, which could improve treatment decisions for affected patients. These findings underscore the urgent need for integrated genomic and immunophenotypic approaches in the diagnosis of ambiguous and mixed-lineage leukemias.
American journal of clinical pathology
Source →Pristimerin drives ROS-dependent apoptosis in cutaneous T-cell lymphoma via inhibition of the AKT-SKP2 axis.
Kuttikrishnan S, et al
Researchers investigated the anti-cancer potential of pristimerin (PS), a natural plant-derived compound, against cutaneous T-cell lymphoma (CTCL), a form of skin cancer for which better treatments are urgently needed. In laboratory experiments using two CTCL cell lines, PS was found to powerfully suppress cell growth and trigger apoptosis — programmed cell death — through the mitochondrial pathway, activating a cascade of cell-killing proteins including caspases. The compound worked by inhibiting the AKT-SKP2 signaling axis, which led to accumulation of proteins that put the brakes on cancer cell division, while also reducing survival factors like XIAP. A key finding was that PS elevated reactive oxygen species (ROS) inside cancer cells, and blocking ROS with the antioxidant N-acetylcysteine significantly reduced PS's toxic effects on the cancer cells, confirming that ROS generation is central to its mechanism of action. Importantly, when PS was combined with bortezomib, an approved proteasome inhibitor, the two drugs worked synergistically to produce greater anti-lymphoma activity than either drug alone. These results suggest that pristimerin-based treatment strategies warrant further investigation as a potential new therapy for cutaneous T-cell lymphoma.
Toxicology and applied pharmacology
Source →Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series.
Satyavarapu I, et al
Researchers published a case series examining how oncologists managed advanced classical Hodgkin lymphoma (cHL) when key chemotherapy drugs — vinblastine and dacarbazine — were in critical short supply in 2023. Classical Hodgkin lymphoma is a highly curable blood cancer typically treated with combination regimens such as ABVD or A+AVD, which rely on these two agents as essential components. Faced with rationing, clinicians administered lower cumulative doses of standard chemotherapy rather than switching entirely to alternative regimens, while closely monitoring patient responses. All three patients described in the series achieved effective treatment outcomes without apparent compromise in cancer control. The findings suggest that a flexible, response-adapted dosing strategy combined with close multidisciplinary collaboration can help maintain treatment efficacy even during drug shortages. This report offers practical guidance for oncology teams navigating similar supply disruptions affecting curative-intent therapies.
Case reports in oncological medicine
Source →Emerging human cell-based in vitro models for studying pituitary development and disorders.
Matsumoto R, et al
A new review published in Endocrine Journal examines the latest human cell-based laboratory models being developed to study the pituitary gland, a small but critical brain structure that governs hormone production throughout the body. Traditional research has relied heavily on animal models such as mice and zebrafish, but biological differences between species have made it difficult to translate these findings directly to human medicine. Recent advances in biotechnology have made it possible to grow human pituitary tumor tissue in long-term laboratory cultures and to generate pituitary hormone-producing cells directly from human pluripotent stem cells, overcoming the historical shortage of human pituitary cell lines. These new platforms are enabling scientists to investigate the molecular mechanisms behind pituitary development and diseases—including pituitary tumors and autoimmune conditions—in a genuinely human biological context. For patients suffering from hormonal disorders caused by pituitary dysfunction, these models represent a significant step toward more accurate disease modeling, drug testing, and ultimately the development of better-targeted therapies.
Endocrine journal
Source →